Press Releases - Neurology

Press Releases - Neurology

Continued growth in 2019 marked by new HD-X product launch, acquisition of the leading neurofilament light (Nf-L) antibody supplier, new corporate headquarters and new ground-breaking neurodegenerative research proving the utility of digital biomarkers ac | July 11, 2019
BILLERICA, Mass.--(BUSINESS WIRE)--
June 26, 2019
Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier
May 06, 2019
Leading global neurology conference will feature 36 new Simoa-powered studies validating the use of Neurofilament light chain (Nf-L) as a potential diagnostic and prognostic biomarker for neurodegeneration   May 06, 2019 11:30 AM Eastern Daylight Time
October 09, 2018
International multiple sclerosis conference features 35 new studies using Simoa technology demonstrating potential of Neurofilament light chain (NfL) as a reliable and sensitive disease biomarker
September 26, 2018
New research marks the latest example of neurofilament light chain (NfL) as a critical biomarker for detecting brain injuries
Business Wire | November 10, 2017
New technology unlocks ultra-sensitive biomarker detection with the potential to advance the diagnosis and treatment of neurological diseases
CAMBRIDGE, MA – April 12, 2011 – Quanterix Corporation, enabling a new generation of diagnostics based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that significant elevations in blood levels of amyloid beta (Aβ) 42 peptide, a component of the plaques that are a…
February 5, 2016
Quanterix announces that is participating in the NFL Health and Safety Update & Interactive Head Health Showcase at Super Bowl 50.
Lexington, Mass. – March 14, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that JAMA Neurology has published a ground-breaking study in which its Simoa (single molecule…
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L